105 related articles for article (PubMed ID: 11245212)
1. Distribution of tripeptidyl peptidase I in human tissues under normal and pathological conditions.
Kida E; Golabek AA; Walus M; Wujek P; Kaczmarski W; Wisniewski KE
J Neuropathol Exp Neurol; 2001 Mar; 60(3):280-92. PubMed ID: 11245212
[TBL] [Abstract][Full Text] [Related]
2. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
Wisniewski KE; Kida E; Walus M; Wujek P; Kaczmarski W; Golabek AA
Eur J Paediatr Neurol; 2001; 5 Suppl A():73-9. PubMed ID: 11589013
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
4. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
Kopan S; Sivasubramaniam U; Warburton MJ
Biochem Biophys Res Commun; 2004 Jun; 319(1):58-65. PubMed ID: 15158442
[TBL] [Abstract][Full Text] [Related]
5. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Sleat DE; Wiseman JA; El-Banna M; Kim KH; Mao Q; Price S; Macauley SL; Sidman RL; Shen MM; Zhao Q; Passini MA; Davidson BL; Stewart GR; Lobel P
J Neurosci; 2004 Oct; 24(41):9117-26. PubMed ID: 15483130
[TBL] [Abstract][Full Text] [Related]
6. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis.
Rawlings ND; Barrett AJ
Biochim Biophys Acta; 1999 Jan; 1429(2):496-500. PubMed ID: 9989235
[TBL] [Abstract][Full Text] [Related]
7. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
8. [Tripeptidyl-peptidase I--distribution, biogenesis, and mechanisms of activation].
Gołabek AA
Postepy Biochem; 2006; 52(1):16-23. PubMed ID: 16869297
[TBL] [Abstract][Full Text] [Related]
9. The expression of tripeptidyl peptidase I in various tissues of rats and mice.
Koike M; Shibata M; Ohsawa Y; Kametaka S; Waguri S; Kominami E; Uchiyama Y
Arch Histol Cytol; 2002 Aug; 65(3):219-32. PubMed ID: 12389661
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I.
Golabek AA; Kida E; Walus M; Wujek P; Mehta P; Wisniewski KE
J Biol Chem; 2003 Feb; 278(9):7135-45. PubMed ID: 12488460
[TBL] [Abstract][Full Text] [Related]
11. Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes.
Warburton MJ; Bernardini F
Neurosci Lett; 2002 Oct; 331(2):99-102. PubMed ID: 12361850
[TBL] [Abstract][Full Text] [Related]
12. Morphological studies on CLN2.
Goebel HH; Kominami E; Neuen-Jacob E; Wheeler RB
Eur J Paediatr Neurol; 2001; 5 Suppl A():203-7. PubMed ID: 11588998
[TBL] [Abstract][Full Text] [Related]
13. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
14. Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo.
Golabek AA; Walus M; Wisniewski KE; Kida E
J Biol Chem; 2005 Mar; 280(9):7550-61. PubMed ID: 15582991
[TBL] [Abstract][Full Text] [Related]
15. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase.
Ezaki J; Takeda-Ezaki M; Kominami E
J Biochem; 2000 Sep; 128(3):509-16. PubMed ID: 10965052
[TBL] [Abstract][Full Text] [Related]
16. Tripeptidyl-peptidase I in health and disease.
Golabek AA; Kida E
Biol Chem; 2006 Aug; 387(8):1091-9. PubMed ID: 16895480
[TBL] [Abstract][Full Text] [Related]
17. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I.
Vines DJ; Warburton MJ
FEBS Lett; 1999 Jan; 443(2):131-5. PubMed ID: 9989590
[TBL] [Abstract][Full Text] [Related]
18. The substrate range of tripeptidyl-peptidase I.
Bernardini F; Warburton MJ
Eur J Paediatr Neurol; 2001; 5 Suppl A():69-72. PubMed ID: 11589011
[TBL] [Abstract][Full Text] [Related]
19. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
[TBL] [Abstract][Full Text] [Related]
20. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
